News Image

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Provided By GlobeNewswire

Last update: Jul 23, 2025

REHOVOT, Israel, July 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today issued the following letter to shareholders from Chief Executive Officer Gil Efron, highlighting the Company’s scientific progress, operational execution, and strategic milestones during the first half of 2025.

Read more at globenewswire.com

PURPLE BIOTECH LTD-ADR

NASDAQ:PPBT (8/18/2025, 12:51:20 PM)

2.22

-0.09 (-3.9%)



Find more stocks in the Stock Screener

Follow ChartMill for more